403. Toca Retroviral Replicating Vector in Tumor and Blood From Clinical Trial Subjects With Recurrent High Grade Glioma

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)33212-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PC3 - 151 Toca 5: A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Patients Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA) (NCT02414165)

Canadian Journal of Neurological Sciences
MedicineNeurology
2016English

PD-L1 Checkpoint Blockade Delivered by Retroviral Replicating Vector Confers Anti-Tumor Efficacy in Murine Tumor Models

Oncotarget
Oncology
2019English

Timing of Surgery and Bevacizumab Therapy in Neurosurgical Patients With Recurrent High Grade Glioma

Journal of Clinical Neuroscience
MedicineSurgeryNeurologyPhysiology
2015English

International Differences in Treatment and Clinical Outcomes for High Grade Glioma

PLoS ONE
Multidisciplinary
2015English

Dual-Vector Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors

Cancer Gene Therapy
Cancer ResearchMolecular MedicineMolecular Biology
2018English

Hypofractionated Stereotactic Radiation Therapy in Recurrent High-Grade Glioma: A New Challenge

Cancer Research and Treatment
Cancer ResearchOncology
2016English

Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma

World Journal of Oncology
Cancer ResearchOncology
2014English

Clinical Significance of FBXO17 Gene Expression in High-Grade Glioma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Combination of 6-Thioguanine, Capecitabine, and Celecoxib With Temozolomide or Lomustine for Recurrent High-Grade Glioma

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy